Journal Articles

Biz AN, Alava MH, Wailoo A. Switching from EQ-5D-3L to EQ-5D-5L in England: the impact in NICE technology appraisals. Value Health. 2026. doi: 10.1016/j.jval.2026.03.007

Keetharuth AD, Mukuria C, Peasgood T, Wailoo A. EQ Health and Wellbeing (EQ-HWB): A psychometric assessment across six conditions and the general population in the United Kingdom. Value Health. 2025. doi: 10.1016/j.jval.2025.07.028

Carlton J, Powell PA, Kirkcaldy A, Rowen D. Determining the Content Validity of the EQ-5D-5L, EQ-5D-Y-3L, and CHU9D Instruments for Assessing Generic Child and Adolescent Health-Related Quality of Life: A Qualitative Study. Patient. 2025. doi: 10.1007/s40271-025-00743-9

Longo F, Claxton K, Salas-Ortiz A, Lomas J, Martin S. Does Publicly-Funded Adult Social Care Impact Informal and Unpaid Carers' Quality of Life in England? Health Econ. 2025. doi: 10.1002/hec.4957

Hussain H, Keetharuth A, Wailoo A, Rowen D. Enhancing HRQoL assessment for economic evaluation in dementia populations. Alzheimer's Dement. 2025;11:e70061. doi: 10.1002/trc2.70061

Woods B, Palacios A, Sculpher M. A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence. Pharmacoeconomics. 2024. doi: 10.1007/s40273-024-01450-3

Woods B, Kearns B, Schmitt L, et al. Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England. Appl Health Econ Health Policy. 2024. doi: 10.1007/s40258-024-00924-x

Woods B, Lomas J, Sculpher M, Weatherly H, Claxton K. Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health Econ. 2024;33(4):804–819. doi: 10.1002/hec.4795

Salas-Ortiz A, Longo F, Claxton K, Lomas J. Unpacking the care-related quality of life effect of England's publicly funded adult social care. A panel data analysis. Health Econ. 2024:1–21. doi: 10.1002/hec.4907

Anderson A, Visintin C, Antoniou A, et al. Risk stratification in breast screening workshop. BMC Proc. 2024;18(Suppl 19):22. doi: 10.1186/s12919-024-00306-0

Hill H, Roadevin C, Duffy S, Mandrik O, Brentnall A. Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening. JAMA Netw Open. 2024;7(9):e2431715. doi: 10.1001/jamanetworkopen.2024.31715

Woods B, Schmitt L, Jankovic D, et al. Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technol Assess. 2024;28(28):1-238. doi: 10.3310/YGWR4511

Powell P, Rowen D, Keetharuth A, Mukuria C, Shah K. Who should value children’s health and how? An international Delphi study. Soc Sci Med. 2024. doi: 10.1016/j.socscimed.2024.117127

Longo F, Claxton K, Griffin S, Mason A, Walker S, Weatherly H. Social Decision-Making Analysis: A General Approach to Inform Decisions on Resources in the Public Sector. Value Health. 2024. doi: 10.1016/j.jval.2024.01.015

Gibbs NK, Griffin S, Gutacker N, Villaseñor A, Walker S. The Health Impact of Waiting for Elective Procedures in the NHS in England: A Modeling Framework Applied to Coronary Artery Bypass Graft and Total Hip Replacement. Med Decis Making. 2024;44(5):572-585. doi: 10.1177/0272989X241256639

Keetharuth AD, Gray LA, McGrane E, et al. Mapping Short Warwick and Edinburgh Mental Wellbeing Scale (SWEMWBS) to Recovering Quality of Life (ReQoL) to estimate health utilities. Health Qual Life Outcomes. 2024;22:7. doi: 10.1186/s12955-023-02220-z

Hill H, Kearns B, Pashayan N, et al. The cost-effectiveness of risk-stratified breast cancer screening in the UK. Br J Cancer. 2023;129(11):1801-1809. doi: 10.1038/s41416-023-02461-1

Powell P, Rowen D, Keetharuth D, Mukuria C. Understanding UK public views on normative decisions made to value health-related quality of life in children: A qualitative study. Soc Sci Med. 2023:116506. doi: 10.1016/j.socscimed.2023.116506

Longo F, Claxton K, Lomas J, et al. Is extending eligibility for adult social care better than investing more in existing users in England? A cross-sectional evidence for multiple financial years. BMJ Open. 2023;13:e070833. doi: 10.1136/bmjopen-2022-070833

Longo F, Claxton K, Martin S, Lomas J. More long-term care for better healthcare and vice versa: investigating the mortality effects of interactions between these public sectors. Fiscal Studies. 2023;00:1–28. doi: 10.1111/1475-5890.12322

Martin S, Claxton K, Lomas J, Longo F. The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17. Health Policy. 2023;132:104800. doi: 10.1016/j.healthpol.2023.104800

Hernández Alava M, Pudney S, Wailoo A. Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study. Pharmacoeconomics. 2023;41:199–207. doi: 10.1007/s40273-022-01218-7

Hussain H, Keetharuth AD, Rowen D, Wailoo A. Convergent validity of EQ-5D with core outcomes in dementia: a systematic review. Health Qual Life Outcomes. 2022;20:152. doi: 10.1186/s12955-022-02062-1

Woods B, Fox A, Sculpher M, Claxton K. Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. Health Econ. 2021:1–18. doi: 10.1002/hec.4393

Hernández-Alava M, Pudney S. Mapping between EQ-5D-3L and EQ-5D-5L: A survey experiment on the validity of multi-instrument data. Health Econ. 2022:1–17. doi: 10.1002/hec.4487

Martin S, Lomas J, Claxton K, Longo F. How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Appl Health Econ Health Policy. 2021. doi: 10.1007/s40258-021-00663-3

Martin S, Longo F, Lomas J, Claxton K. Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014. BMJ Open. 2021;11(10):e046417. doi: 10.1136/bmjopen-2020-046417

Longo F, Claxton K, Lomas J, Martin S. Does public long-term care expenditure improve care-related quality of life of service users in England? Health Econ. 2021. doi: 10.1002/hec.4396

Soares MO, Sculpher MJ, Claxton K. Authors' Response to: "Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al." by Sampson, Firth, and Towse. Med Decis Making. 2021. doi: 10.1177/0272989X20987222

Martin S, Lomas J, Claxton K. Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. BMJ Open. 2020;10(10):e036411. doi: 10.1136/bmjopen-2019-036411

Duarte A, Walker S, Metry A, et al. Jointly modelling economics and epidemiology to support public policy decisions for the COVID‐19 response: a review of UK studies. Pharmacoeconomics. 2021. doi: 10.1007/s40273-021-01045-2

Wailoo A, Hernández Alava M, Pudney S, et al. An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis. Value Health. 2021. doi: 10.1016/j.jval.2020.11.012

Elliott RA, Camacho E, Jankovic D, Sculpher MJ, Faria R. Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf. 2020. doi: 10.1136/bmjqs-2019-010206

Hernandez M, Pudney S, Wailoo A. The EQ-5D-5L Value Set for England: Findings of a Quality Assurance Program. Value Health. 2020;23(5):642-648. doi: 10.1016/j.jval.2019.10.017

Soares MO, Sculpher MJ, Claxton K. Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts. Med Decis Making. 2020;40(4):448-459. doi: 10.1177/0272989X20916450

Stevens K, Brazier J, Rowen D. Estimating an exchange rate between the EQ-5D-3L and ASCOT. Eur J Health Econ. 2018;19:653. doi: 10.1007/s10198-017-0910-x

Keetharuth A, Brazier J, Connell J, et al. Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties. Br J Psychiatry. 2018;212(1):42-49. doi: 10.1192/bjp.2017.10

Espinoza MA, Manca A, Claxton K, Sculpher M. Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system. Health Econ. 2017. doi: 10.1002/hec.3559

Faria R, Woods B, Griffin S, Palmer S, Sculpher M, Ryder SD. Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Aliment Pharmacol Ther. 2016;44:866–876. doi: 10.1111/apt.13775